Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.09
-0.35 (-4.21%)
Aug 26, 2026, 4:00 PM EDT - Market closed

Iovance Biotherapeutics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, Iovance Biotherapeutics stock has a consensus rating of "Buy" and an average price target of $10. The average 1-year stock price forecast is 23.69% higher than the current stock price, while the lowest is $6.00 (-25.79%) and the highest is $14 (+73.16%).

Price Target: $10 (+23.69%)
Analyst Consensus: Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$6.00$10$10$14
Change-25.79%+23.69%+23.69%+73.16%

Analyst Ratings

The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart
RatingMar '26Apr '26May '26Jun '26Jul '26Aug '26
Strong Buy666655
Buy222222
Hold332222
Sell000000
Strong Sell000000
Total1111101099

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
TD Cowen
TD Cowen
Buy
Reiterates
$7$10
BuyReiterates$7$10+23.69%Aug 25, 2026
UBS
UBS
Hold
Reiterates
$4$7
HoldReiterates$4$7-13.42%Aug 20, 2026
Mizuho Securities
Mizuho Securities
Buy
Maintains
$10$11
BuyMaintains$10$11+36.05%Aug 17, 2026
Robert W. Baird
Robert W. Baird
Hold
Maintains
$4$6
HoldMaintains$4$6-25.79%Aug 7, 2026
Citizens JMP
Citizens JMP
Buy
Maintains
$5$8
BuyMaintains$5$8-1.05%Aug 7, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
412.17M
from 263.50M
Increased by 56.42%
Revenue Next Year
569.31M
from 412.17M
Increased by 38.13%
EPS This Year
-0.48
from -1.09
EPS Next Year
-0.27
from -0.48
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
--1.19M164.07M263.50M412.17M
Revenue Growth
---13,698.99%60.60%56.42%
Operating Income
-342.70M-398.88M-460.56M-395.28M-398.21M-215.19M
Net Income
-342.25M-395.89M-444.04M-372.18M-390.98M-205.05M
EPS
-----1.09-0.48
Free Cash Flow
-129.35M-173.54M-211.47M-198.76M-162.42M-122.00M
No. Analysts
-----8
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High470.0M
Avg412.2M
Low375.0M

Revenue Growth

Revenue Growth202620272028
High
78.4%
Avg
56.4%
Low
42.3%

EPS Forecast

EPS202620272028
High-0.40
Avg-0.48
Low-0.58

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-